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INTRODUCTION
Familial hypokalemic periodic paralysis (HOPP) is an auto-
somal dominant skeletal muscle ion channelopathy result-
ing in episodic attacks of muscle weakness with concomi-
tant hypokalemia. Familial HOPP is the most prevalent
form of periodic paralysis, but it is still a rare disorder (the
prevalence is estimated at about 1/100,000) (1). The onset
of this disease is usually in the first or second decade of life.
Acute crises most frequently occur at night and in the early
morning, and last for hours, sometimes days. Although the
frequency of attacks is variable, ranging from a few in a life
time to daily attacks, it is maximal between ages 15 and 35
yr and then decreases with age (2, 3). The precipitating fac-
tors consist mainly of carbohydrate- or sodium-rich meals,
emotional stress, exposure to cold, and strenuous exercise.
Molecular genetic analysis has shown that familial HOPP
is caused by mutations in a calcium channel gene (CACN-
A1S) or a sodium channel gene (SCN4A) (4). The majority
(70%) of familial HOPP patients have missense mutations
in the CACNA1S gene located on chromosome 1q32 (4, 5).
The CACNA1S gene encodes the alpha 1-subunit of a skele-
tal muscle calcium channel protein (6). To date, three causa-
tive HOPP mutations have been identified in the highly con-
served putative membrane spanning domains (Arg528His,
Arg1239His, and Arg1239Gly) of the calcium channel pro-
tein (6, 7). Five missense mutations in SCN4A gene have
been implicated in familial HOPP. These include Arg669His,
Arg672Ser, Arg672His, Arg672Gly, and Arg672Cys (8-10).
In a previous large-scale study, missense mutations in the
sodium channel gene were found in about 9% of HOPP fa-
milies (11).
The phenotypes of each mutation have some differences
in gender penetrance and the clinical characteristics, includ-
ing the response to medications (12-14). Comparison be-
tween the males and females with disease-causing mutations
has shown that the symptoms are less frequent in females
than in males (12). Acetazolamide is a carbonic anhydrase
inhibitor, and it has been considered to be highly effective
for treating most HOPP patients. However, several patients
with the Arg672Gly SCN4A mutation and a patient with
the Arg672Ser SCN4A mutation showed an exacerbation of
their symptoms after acetazolamide treatment (4, 14). In light
of this information, which is possibly based on the genetic
or allelic heterogeneity found in familial HOPP patients,
further understanding of the genotype and characteristic
phenotype of this disorder has been suggested to be useful
for facilitating the diagnosis and providing appropriate treat-
ment (15, 16). The number of Asian patients with familial
HOPP is presumed to be much smaller than that of patients
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The Genotype and Clinical Phenotype of Korean Patients with
Familial Hypokalemic Periodic Paralysis
Familial hypokalemic periodic paralysis (HOPP) is a rare autosomal-dominant dis-
ease characterized by reversible attacks of muscle weakness occurring with epi-
sodic hypokalemia. Mutations in the skeletal muscle calcium (CACNA1S) and so-
dium channel (SCN4A) genes have been reported to be responsible for familial
HOPP. Fifty-one HOPP patients from 20 Korean families were studied to deter-
mine the relative frequency of the known mutations and to specify the clinical fea-
tures associated with the identified mutations. DNA analysis identified known muta-
tions in 12 families: 9 (75%) were linked to the CACNA1S gene and 3 (25%) to the
SCN4A gene. The Arg528His mutation in the CACNA1S gene was found to be
predominant in these 12 families. Additionally, we have detected one novel silent
exonic mutation (1950C>T) in the SCN4A gene. As for a SCN4A Arg669His muta-
tion, incomplete penetrance in a woman was observed. Characteristic clinical fea-
tures were observed both in patients with and without mutations. This study pre-
sents comprehensive data on the genotype and phenotype of Korean families with
HOPP.
Key Words : Hypokalemic Periodic Paralysis; Calcium Channels; Sodium Channels; Mutation
Received : 7 February 2007
Accepted : 22 May 2007The Genotype and Clinical Phenotype of Korean Patients with Familial Hypokalemic Periodic Paralysis 947
in Western countries (17, 18). Relatively little work on direct
comparisons of patients with and without known mutations
has been done to date. In the present study, each index case
and some relatives from 20 Korean families with HOPP were
screened for the eight known causative mutations in the CA-
CNA1S and SCN4A genes. The purpose of this study was
to determine the relative frequency of the known mutations
and to ascertain the clinical features of those with or without
these mutations.
MATERIALS AND METHODS
Subjects
We identified 51 patients who were diagnosed with HOPP
from January 2000 to June 2006 at the clinics of the Catholic
University of Korea, the Seoul National University, and the
Samsung Medical Center. All of the clinical and mutation
data, except those of the patients in five families, were ob-
tained prospectively from the Department of Pediatrics at
the Catholic University of Korea. The clinical details of four
families have been previously reported (19, 20). The search
for a causal mutation was undertaken in 20 independent
probands having the diagnosis of HOPP and also in some of
their relatives. All the patients fulfilled the diagnostic crite-
ria for HOPP: 1) each patient had episodic paralysis; 2) one
or more members of each kindred had shown a low serum
potassium level (<3.5 mEq/L) during attacks of weakness;
and 3) myotonia was neither clinically present nor detectable
by electromyography. We confirmed the absence of secondary
causes of hypokalemia, such as thyrotoxicosis, hyperaldos-
teronism, and renal tubular acidosis. Blood samples were
obtained with given informed consent from all participants
in compliance with the institutional review board of the
Catholic University of Korea, College of Medicine. 
Mutation analysis
Each proband was initially screened for the known causa-
tive mutations in the CACNA1S gene (Arg528His, Arg-
1239His, and Arg1239Gly). The Arg528His, Arg1239His,
and Arg1239Gly mutations disrupt the Bbv 1, Sau 96 I, and
Bsp LU III restriction sites, respectively. The restriction ana-
lysis products of the patients were compared with those of
the three known mutations (controls). For those patients in
whom a mutation was not identified in the CACNA1S gene,
direct sequence analysis of exon 12 of the SCN4A gene was
performed. Molecular genetic screening for known mutations
was available as a commercial clinical service at the Neuro-
genetics DNA Diagnostic Lab, Massachusetts General Hos-
pital (Boston, MA, U.S.A.). In all the affected members of
one family with HOPP, sequencing of exon 12 of the SCN4A
gene did not identify any of the 5 previously reported muta-
tions. However, a heterozygous silent mutation (1950C>T)
was found in the exon 12. We searched for the same change
in 50 unrelated and unaffected Koreans by performing a poly-
merase chain reaction (PCR) and analyzing the PCR products
by means of restriction digestion analysis and sequencing.
From each control individual, a 273-bp fragment contain-
ing the transition site was amplified by PCR. Primers used
were 5′ -GTGGGAGTTGGGTGGGAGAC-3′(F) and
5′ -CCTGGCCCTGGGCTTTTGTG-3′ (R). PCR was per-
formed on 50  L of standard PCR buffer containing 2 mM
MgCl2, 250  M of each dNTP, 10 pmole of each primer, 1
unit of i-MAX II Taq polymerase (Intron biotechnology,
Seoul, Korea), and 100 ng genomic DNA. The PCR prod-
ucts were electrophoresed on 1.8% agarose gel, and the ampli-
fied genomic DNA fragments were extracted from the gel
and then purified using the method described by the manu-
facturer’s recommended protocol (QIAquick
� gel extraction
kit; Quiagen, Hilden, Germany). The C-to-T alteration at
nucleotide position 1950 in exon 12 of the SCN4A gene
destroys a Hph I restriction site, thus permitting the change
to be screened by restriction analysis with Hph I. A 25- L
aliquot of each 273-bp PCR product was mixed with 1 IU
of Hph I (New England BioLabs Inc; Ipswich, MA, U.S.A.),
5  L of appropriate 10X buffer and 19.8  L of H2O. The
mixtures were left at 37℃ for 16 hr. The resulting diges-
tion products were electrophoresed on 1.8% agarose gel.
Direct sequencing was performed according to the manu-
facturer’s protocol (ABI 3700; Applied-Biosystems, Foster
city, CA, U.S.A.). 
Statistical anaysis
Statistical anaysis was performed using SPSS for windows
13.0 (SPSS Inc., Chicago, IL, U.S.A.). Data were analysed
with nonparametric tests (Mann-Whitney). Statistical data
were expressed as mean, unless indicated otherwise. p<0.05
was considered statistically significant.
RESULTS
Mutation analysis 
The screening for known HOPP mutations in 20 inde-
pendent index cases showed 12 families (60%) with muta-
tions in either the calcium channel gene or the sodium chan-
nel gene (Table 1). Calcium channel mutations were found
in 9 families, and sodium channel mutations in 3 families.
The following distribution was found amongst those with
calcium channel mutations: 6 cases with Arg528His (4 famil-
ial, 2 sporadic), 2 cases with Arg1239His (familial), and one
case carrying Arg1239Gly (familial). The Arg528His muta-
tion was the most common cause of familial HOPP in the
present study.948 J.-B. Kim, M.-H. Kim, S.J. Lee, et al.
Incomplete penetrance was observed in a woman with
Arg669His SCN4A mutation: she was the mother of a male
patient who carried the same Arg669His mutation, but she
had never experienced any paralytic attacks in her lifetime
(Fig. 1). In one proband, a heterozygous C-to-T transition
was identified at nucleotide 1950 in exon 12 of the SCN4A
gene. This alteration does not predict an amino acid change
at codon 650. The same change was confirmed in the DNA
of the proband’s mother, who had similar attacks of paraly-
sis. Other members of the family were not affected, and the
samples from them were not available. This change has not
been reported previously. We confirmed its absence in 50
unaffected and unrelated Korean individuals, i.e., 100 chro-
mosomes. 
Genotypes and phenotypes in HOPP patients 
Table 2 describes the clinical characteristics for Korean
patients with HOPP. The mean age at onset of the disease
was younger in those with mutations (average, 11 yr; range,
1-19 yr) than in those without (average, 17 yr; range, 1-34
yr) (p<0.05). Patients with the Arg1239Gly CACNA1S
mutation presented at the earliest age (average, 2.6 yr) (p<
0.05). The patient with the Arg669His SCN4A mutation
had much shorter attacks that were on average 1 hr-long, com-
pared with those with the Arg1239Gly mutation, for whom
the average length of the attacks was 16 hr (p<0.05). Patients
with the Arg528His CACNA1S mutation had attacks, on
average, once per month. In contrast, patients with the Arg-
1239Gly CACNA1S and Arg672Gly SCN4A mutations
had daily attacks even after the age of 30. Postcritic myal-
gias were reported in 18 patients with Arg528His and one
patient with Arg669His in whom the myalgias could last
from several minutes to hours. Both percritic and postcritic
myalgias were reported in one patient with Arg672Cys and
in one index case without mutations. All the affected mem-
bers of the family with the Arg1239Gly mutation displayed
bilateral ankle equinus. This deformity seemed to be slowly
progressive. One affected member of the family underwent
muscle biopsy and electrodiagnostic study, including nerve
conduction study and needle electromyogram. No definite
abnormality was found on either studies. Strenuous exercise
was the most common triggering factor for an attack both
in those with and without mutations. Carbohydrate- or sodi-
um-rich meals were another common precipitant. Compared
with those with other mutations, the patients with Arg528His
were less sensitive to cold exposure (p<0.05). Although alco-
hol intake was frequently reported as a provocative factor in
many cases, all patients with Arg1239His and most of pati-
ents with Arg528His patients did not complain of paralytic
attacks after alcohol consumption. Prophylactic acetazolamide
treatment was administered to most cases. One patient with
the Arg1239Gly mutation, one patient with the Arg672Gly
mutation, and two patients in different kindreds without
mutations reported worsening of their symptoms with aceta-
zolamide treatment. These patients were successfully treat-
ed with a combination of oral spironolactone, amiloride, and
potassium supplementation. The severe paralytic attacks in
patients with the Arg1239Gly, Arg528His, Arg672Gly,
and Arg672Cys mutations were often accompanied by res-
piratory distress. 
Type Families Patients
All HOPP 20 51
HOPP without mutations  8 (40%) 14 (27%)
HOPP with mutations  12 (60%) 37 (73%)
CACNA1S gene 9 (75%, 9/12) 32 (86%, 32/37)
Arg528His 6  22
Arg1239His 2 4
Arg1239Gly 1 6
SCN4A gene 3 (25%, 3/12) 5 (14%, 5/37)
Arg669His 1 1
Arg672Gly 1 3
Arg672Cys 1 1
Table 1. Results of molecular genetic testing in Korean families
with HOPP
Fig. 1. Pedigree of a family with the SCN4A Arg669His mutation. Dark symbols represent the affected individuals. The symbol with a dot
designates an asymptomatic carrier. Slash marks represent deceased individuals. The proband is indicated by an arrow. The age of the
family members is designated by the number. 
49 51 46 50 44 48 42 45 40 44
25 20 18 16 15 18
HOPP, hypokalemic periodic paralysis. 
All except one patient with Arg672Cys and two patients with Arg528His
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DISCUSSION
We investigated the molecular genetic basis of 20 Korean
families suffering from HOPP. Twelve families (60%) had
known mutations in either the calcium channel or the sodi-
um channel. When considering the previous notion of the low
prevalence of Asian HOPP patients with mutations (17, 18),
this figure is high and analogous to those reported in the
previous Western studies (4, 11). Eight probands remained
without the known mutations, and three of them had other
affected members in their families. Compared to the patients
with known mutations, those without mutations showed an
older age at onset of their disease. Although they did not have
electrodiagnostic studies or muscle biopsies performed, over-
all, they had the typical clinical features, including dietary
triggers and their response to medications. Given that the
allelic or genetic heterogeneity of HOPP has been consis-
tently suggested, undescribed mutations are likely to be dis-
covered in these kindreds. We have to admit the limitation
in the level of the genetic analysis at this stage, but we have
already been performing sequencing for novel mutations in
the CACNA1S gene for the mutation-negative cases and link-
age studies to exclude the two loci for the familial cases with-
out mutations. In comparison with the previous study (11)
that showed the majority were secondary to both Arg528His
and Arg1239His CACNA1S mutations, the Arg528His
mutation alone was predominant in the present study. The
observation of the identical mutation in unrelated families
and de novo mutations as already described (20) argues in
favor of the recurrent mutation in the CACNA1S gene, which
may contribute to the predominance of this mutation in the
Korean population.
Some genotype-phenotype correlations in HOPP patients
are emerging. As shown by the clinical details in Table 2,
some of the clinical phenotypes displayed by our series of
families and the previously reported families were similar.
One asymptomatic female case with the Arg669His SCN4A
mutation was documented, which is consistent with the gen-
eral observation that the phenotype of HOPP is often less
pronounced in females. There were certain phenotypic differ-
ences, however, between the previous studies and our results.
Patients with the Arg672Gly SCN4A mutation in the pre-
sent study showed an earlier age of onset of the disease than
that in the previous report (4), and they did not display pos-
tictal myalgias and cramps. In contrast to the previous report
(11), the patient with Arg672Cys did not complain of wors-
ening after potassium intake. Potassium administration res-
tored the patients’ strength during attacks. Emotional stress-
induced weakness was present in 32% of those with the Arg-
528His CACNA1S mutation. This result stands in contrast
Clinical
findings
HOPP with mutations (n=37)
CACNA1S (n=32)
Arg1239Gly
(n=6)
Arg1239His
(n=4)
Arg528His
(n=22)
HOPP without
mutations 
(n=14)
SCN4A (n=5)
Arg669His 
(n=1) 
Arg672Gly
(n=3)
Arg672Cys
(n=1)
Age at onset, yr  2.6±1.4 9.3±2.2 15.3±2.9 17 6.7±1.2 12 17.3±11.3
(range) (1-3) (8-12) (10-19) (6-8) (1-34)
Duration of attacks, hr  16.0±1.1 2.8±0.5 13.3±9.4 1 5.3±0.6 10 6.1±1.0 
(range) (12-72) (2-48) (4-72) (1-36) (5-6) (8-16) (5-96)
Frequency of attacks/mo Daily 23.0±14.0 1.2±0.9 (3-4) Daily (2-3) 5.3±9.2
(range) (2-30) (0.1-4) (1-30)
Associated myalgias, % 0% 0% Postcritic, Postcritic 0% Per- &  Per- & postcritic,
(number of patients) 82% (n=18) postcritic 8% (n=1)
Precipitating factors, %
Exercise 100% 100% 100% 100% 100% 100% 92%
Sweets 100% 100% 91% 100% 100% 100% 83%
Salt 100% 100% 91% 100% 100% 100% 83%
Stress 100% 100% 32% 100% 100% 100% 75%
Cold 100% 100% 68% 100% 100% 100% 75%
Alcohol 100% 0% 5% 100% 67% 100% 67%
Response to acetazolamide 3 cases 1 case 5 cases 1 case 1 case  1 case 6 cases 
(M: 3)  (M: 1)  (M: 4, F: 1) (M: 1) (M: 1) (M: 1) (M: 6)
No effect  No effect  Beneficial No effect Deleterious No effect Deleterious
(n=2) (n=2) (n=2)
Deleterious  No effect No effect
(n=1) (n=3) (n=4
Respiratory difficulty in  6 cases None 3 cases None 3 cases 2 cases None
severe state (M: 3, F: 3) (M: 3) (M: 2, F: 1)  (M: 2)
Table 2. Clinical features of HOPP patients with different mutations
*HOPP, hypokalemic periodic paralysis. Values are means±SD.950 J.-B. Kim, M.-H. Kim, S.J. Lee, et al.
to the previous finding (11), that weakness is rare in the pa-
tients with Arg528His following exposure to acute stress.
In addition, compared with the attack frequency reported
by Miller et al. (11) for their patients with Arg528His, a
low frequency of attacks was observed for the Korean patients
with Arg528His. However, the prevalence of each of the dif-
ferent precipitating factors was higher in the Korean patients
with Arg528His than in Miller’s patients with Arg528His.
There may have been a different way in assessing precipitat-
ing factors or a difference in exposition to precipitating fac-
tors. Otherwise, these differences, overall, may support the
earlier suggestion of the modifying influence of other uniden-
tified genetic factors (21). 
We observed one novel silent mutation (1950C>T) in exon
12 of the SCN4A gene. Samples from unaffected siblings
were not available. We confirmed its absence in 50 unaffect-
ed and unrelated Korean individuals. There have been reports
showing that silent mutations can also be pathogenic by cre-
ating a new cryptic splicing site or by interrupting other func-
tional processes in the nucleus (22, 23). Given that C1950
is located near the middle of exon 12, however, we are not
considering conducting further studies to exclude this single-
base substitution as a rare sequence variant. Instead, we have
already been performing an exhaustive screening of other
regions of the CACNA1S and SCN4A in this and other HOPP
families without known mutations. Additional studies such
as RT-PCR analysis to test for aberrant pre-mRNA splicing
will be required to establish a possible pathogenic role of
1950C>T.
All the known mutations causing HOPP change positive-
ly charged arginines to weakly charged amino acid residues
in the voltage-gated calcium (CACNA1S) and sodium (SC-
N4A) channels. The functional effects of the mutations have
been investigated by electrophysiologic studies of in vitro
expression systems. Altogether, those mutations reduce the
respective ion current density and result in a slow activation
of each ion channel. However, the linkage between the elec-
trophysologic defects of the mutations and hypokalemia re-
mains to be elucidated.
Acetazolamide has been reported to increase the frequen-
cy and the severity of attacks in some HOPP patients with
either a specific calcium channel mutation or sodium chan-
nel mutation (4, 11, 14). Before performing genetic testing,
we preferred to use spironolactone and its derivatives, which
have been used as alternatives to acetazolamide if the latter
was ineffective after the initial empirical use (24, 25). In the
present study, none of the patients who were prescribed a
combination of oral spironolactone, amiloride, and potassi-
um supplementation reported exacerbation of their symp-
toms or other side effects, including gynecomastia. 
In conclusion, we identified the known genetic defects
underlying the HOPP in 60% of the individuals we tested.
These included the Arg528His, Arg1239His, and Arg1239-
Gly mutations in the CACNA1S gene and the Arg669His,
Arg672Gly, and Arg672Cys mutations in the SCN4A gene.
The Arg528His mutation was the most common cause of
familial HOPP in the present study. An asymptomatic case
of a woman with an Arg669His mutation was observed. We
also found a novel silent mutation, which is most likely a
single nucleotide polymorphism, in the SCN4A gene. Some
characteristic clinical features were observed in the patients
with and without the previously reported mutations. Al-
though a strict correlation may be difficult to establish for
some genotypes due to the small number of families, fur-
ther collection of this type of data will help clarify the clini-
cal phenotypes, and this will lead to a better understanding
of the disease and help to provide appropriate treatment. 
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